4/23
08:09 am
legn
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
Low
Report
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
4/22
01:20 pm
legn
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma [Yahoo! Finance]
Low
Report
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma [Yahoo! Finance]
4/22
01:05 pm
legn
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Low
Report
CARVYKTI® (ciltacabtagene autoleucel) Approved by the European Commission for Second-line Treatment of Patients with Relapsed and Refractory Multiple Myeloma
4/18
09:00 am
legn
Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency"
Medium
Report
Bluecrux & Pharmaceutical Innovator Forge Path Toward QC & Supply Chain Integration: "Revolutionizing Lab Operations for Enhanced Efficiency"
4/17
03:01 pm
legn
Legend Biotech Co. (NASDAQ: LEGN) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $65.00 price target on the stock.
Low
Report
Legend Biotech Co. (NASDAQ: LEGN) was upgraded by analysts at Scotiabank from a "sector perform" rating to a "sector outperform" rating. They now have a $65.00 price target on the stock.
4/16
01:18 pm
legn
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
Low
Report
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
4/11
08:00 am
legn
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
Low
Report
Legend Biotech to Host Investor Conference Call on First Quarter 2024 Results
4/8
11:45 am
legn
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma [Yahoo! Finance]
Low
Report
FDA Expands J&J's (JNJ) Carvykti Label in Multiple Myeloma [Yahoo! Finance]
4/8
10:42 am
legn
Why Legend Biotech (LEGN) Stock Might be a Great Pick [Yahoo! Finance]
Low
Report
Why Legend Biotech (LEGN) Stock Might be a Great Pick [Yahoo! Finance]
4/6
08:44 am
legn
Johnson & Johnson wins FDA nod for Carvykti label expansion [Seeking Alpha]
Low
Report
Johnson & Johnson wins FDA nod for Carvykti label expansion [Seeking Alpha]
4/5
11:46 pm
legn
U.S. FDA approves expanded use of J&J's cancer cell therapy [Reuters]
Low
Report
U.S. FDA approves expanded use of J&J's cancer cell therapy [Reuters]
4/5
11:39 pm
legn
Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma [Yahoo! Finance]
Low
Report
Legend Biotech's CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma [Yahoo! Finance]
4/5
11:30 pm
legn
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
Low
Report
Legend Biotech’s CARVYKTI® (ciltacabtagene autoleucel) Becomes the First and Only BCMA-Targeted CAR-T Cell Therapy Approved by the FDA for Second-Line Treatment of Multiple Myeloma
4/3
07:27 am
legn
Legend Biotech Co. (NASDAQ: LEGN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $82.00 price target on the stock.
Low
Report
Legend Biotech Co. (NASDAQ: LEGN) is now covered by analysts at Cantor Fitzgerald. They set an "overweight" rating and a $82.00 price target on the stock.
4/3
05:54 am
legn
Should You Continue to Hold Legend Biotech Corporation (LEGN)? [Yahoo! Finance]
Low
Report
Should You Continue to Hold Legend Biotech Corporation (LEGN)? [Yahoo! Finance]
4/1
08:09 am
legn
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
Low
Report
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
3/29
05:23 am
legn
Management's Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4 [Yahoo! Finance]
Low
Report
Management's Conservative Guidance Led Legend Biotech Corporation (LEGN) to Decline in Q4 [Yahoo! Finance]
3/20
07:15 am
legn
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy [Seeking Alpha]
Low
Report
GenScript Losses Shrink On Strong Growth For Cancer Cell Therapy [Seeking Alpha]
3/19
08:33 am
legn
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report [Yahoo! Finance]
Low
Report
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report [Yahoo! Finance]
3/19
08:30 am
legn
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
Low
Report
Legend Biotech Announces Publication of Inaugural Environmental, Social and Governance (ESG) Report
3/18
02:53 pm
legn
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
Low
Report
Legend Biotech Co. (NASDAQ: LEGN) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $87.00 price target on the stock.
3/18
02:50 pm
legn
Legend Biotech Co. (NASDAQ: LEGN) had its price target raised by analysts at UBS Group AG from $76.00 to $81.00. They now have a "buy" rating on the stock.
Low
Report
Legend Biotech Co. (NASDAQ: LEGN) had its price target raised by analysts at UBS Group AG from $76.00 to $81.00. They now have a "buy" rating on the stock.
3/15
03:26 pm
legn
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma [Yahoo! Finance]
Low
Report
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma [Yahoo! Finance]
3/15
03:15 pm
legn
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
Low
Report
CARVYKTI® (ciltacabtagene autoleucel) Receives Recommendation from the U.S. FDA Oncologic Drugs Advisory Committee for Earlier Treatment of Patients with Relapsed/Refractory Multiple Myeloma
3/15
06:52 am
legn
Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade) [Seeking Alpha]
Medium
Report
Legend Biotech: AdCom Documents Shed Light On Carvykti's Problems (Downgrade) [Seeking Alpha]